Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
| 3.224 | |
| 3.224 | |
| - | |
| 3.224 | |
| 3.224 | |
| 1.375-4.232 | |
| 230 M | |
| 70 558 K | |
| 74 234 K | |
| -0.07 | |
| 2.121 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
It is a pleasure to report that the Codexis, Inc. (NASDAQ:CDXS) is up 46% in the last quarter. But that doesn't change the fact that the returns over the last three years have been stomach churning. I...
Overview of Baillie Gifford (Trades, Portfolio)'s Recent Transaction Warning! GuruFocus has detected 6 Warning Signs with CDXS. On December 1, 2023, Baillie Gifford (Trades, Portfolio), a renowned i...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
